Rx Prescripttion Only-YMYL Medical Content

Baricent 4 mg (Baricitinib)

Baricitinib 4mg tablets – Incepta Pharmaceuticals Ltd.

Approved for adults with moderate-to-severe rheumatoid arthritis (RA) with inadequate response to one or more TNF inhibitors, and for severe alopecia areata and moderate-to-severe atopic dermatitis in eligible adults.

~70%

ACR20 response rate at 12 weeks vs ~40% placebo (RA-BEAM trial)

Once

Daily oral dosing — no injections required

~35%

Of alopecia areata patients achieved significant scalp hair regrowth (BRAVE trials)

JAK1/2

Selective inhibitor — targets inflammatory signaling pathways

Confirm diagnosis and prior treatment history

Typically considered after inadequate response or intolerance to methotrexate and/or one or more TNF inhibitors (RA), or after other systemic options for alopecia areata/atopic dermatitis.

Screen for infections before starting

Tuberculosis (TB), hepatitis B and C screening required; active infections must be treated or ruled out first.

Review cardiovascular and clotting risk factors

Age 50+, current or past smoking, history of heart attack, stroke, or blood clots significantly affect the risk-benefit discussion — this is a class warning for JAK inhibitors.

Discuss your goals of care

Weigh symptom control and quality-of-life benefit against infection, clotting, cardiovascular, and cancer risk monitoring requirements.

Important safety information — boxed warnings: Baricitinib carries boxed warnings for serious infections, increased risk of death, malignancy (including lymphoma), major adverse cardiovascular events (MACE) such as heart attack and stroke, and thrombosis (blood clots in the lungs, veins, and arteries). These risks are based on long-term safety data across the JAK inhibitor class and are most relevant for patients 50 years or older with at least one cardiovascular risk factor.

Medical Oncologist Review

Board-certified oncologist · 12+ years in thoracic malignancies

“Baricitinib offers meaningful relief for patients who haven’t responded to TNF inhibitors, with the convenience of a daily pill instead of injections. The infection and cardiovascular risks are real, which is why pre-treatment screening and ongoing monitoring aren’t optional — they’re part of using this medication safely.”

Content reviewed against FDA prescribing information, NCCN Guidelines v2.2024, and published Phase III trial data. Last updated June 2026.

Ready to discuss Tagrisso with your care team?

These steps help you have an informed conversation. A confirmed EGFR mutation result is the starting point for any treatment decision.

Questions to ask my healthcare provider

What questions should I ask my rheumatologist about starting Baricitinib 4 mg?

Before confirming baricitinib as your treatment

What treatments have I already tried, and why is baricitinib being considered now — inadequate response, intolerance, or something else?
Why baricitinib specifically, versus a biologic (like a different TNF inhibitor) or another JAK inhibitor?
What dose will I start on, and how is it adjusted based on response or kidney function?

About the boxed warnings — this is the most important section

Do I need TB and hepatitis B/C screening before starting, and what happens if any of those come back positive?
Am I in the higher-risk group for cardiovascular events and blood clots — meaning am I 50 or older with a cardiovascular risk factor like smoking, high blood pressure, or prior heart issues?
What are the warning signs of a blood clot (DVT/PE) — leg swelling, pain, sudden shortness of breath — that should send me to the ER immediately?
What symptoms of a heart attack or stroke should I be alert to while on this medication?
How will I be monitored for infections, especially shingles (herpes zoster), which is more common on this drug?
Will I need regular blood tests for cholesterol, liver enzymes, and blood cell counts — and how often?

About vaccinations and infection prevention

Do I need any vaccines (especially the shingles vaccine) before starting treatment?
Are live vaccines off-limits while I’m on this medication?
What should I do if I develop a cold, infection, or fever while on baricitinib — pause the medication or just monitor?

About what to expect

How long before I notice symptom improvement, and how will we measure whether it’s working (joint counts, inflammatory markers, etc.)?
Are there foods, supplements, or other medications I should avoid?
Since it’s a once-daily pill, does timing matter — with food, same time each day?

About my specific situation

If I’m of childbearing potential, what precautions are needed during treatment, and for how long after stopping?
How does baricitinib interact with my current medications, particularly anything for blood pressure, cholesterol, or blood thinners?
Does my kidney function affect my dose?

About the longer road

If baricitinib doesn’t work well enough, or if side effects become a problem, what’s the next step?
If I respond well, is there a possibility of dose reduction over time?
Are there patient assistance programs through the manufacturer if cost is a barrier?

A practical tip: Given the cardiovascular and clotting boxed warnings, it’s worth specifically asking whether your rheumatologist will coordinate with your primary care doctor (or a cardiologist, if relevant) for ongoing risk monitoring — not just at the start of treatment.

compare with other therapies

Compare baricitinib vs other JAK inhibitors like tofacitinib and upadacitinib

Here’s how the three JAK inhibitors compare. Unlike the ponatinib comparison (where one drug occupied a distinct niche), these three are genuine alternatives competing for similar patients — selectivity and indication breadth are the main differentiators.

Generation and selectivity

	Tofacitinib (Xeljanz)	Baricitinib (Olumiant)	Upadacitinib (Rinvoq)
Approved	2012	2018	2019
JAK selectivity	Pan-JAK (JAK1/JAK3, some JAK2)	JAK1/JAK2 selective	JAK1 selective
Dosing	5mg twice daily (or 11mg XR once daily)	2mg or 4mg once daily	15mg once daily (higher doses for other indications)
First to market	Yes — first oral JAK inhibitor approved for RA	Second	Most recent of the three

The selectivity differences matter in theory — JAK1 is more associated with inflammatory signaling, while JAK2 involvement is linked to effects on blood cell production. In practice, the clinical safety differences between these drugs have turned out to be smaller than their selectivity profiles might suggest.

The shared boxed warnings — why all three look similar here

This is the most important point: all three carry essentially the same boxed warnings (serious infections, mortality, malignancy, MACE, thrombosis), even though tofacitinib was the one actually studied in the trial that triggered them.

The ORAL Surveillance trial compared tofacitinib against TNF inhibitors in RA patients aged 50+ with at least one cardiovascular risk factor, and found increased rates of cardiovascular events, blood clots, and cancer with tofacitinib. Regulatory agencies then extended these boxed warnings to the entire JAK inhibitor class — including baricitinib and upadacitinib — as a precaution, even though dedicated trials of that scale weren’t repeated for each drug individually.

This means: if you’re in the higher-risk group (50+, with a cardiovascular risk factor), all three carry the same labeled warnings, and the choice between them often comes down to other factors.

Efficacy and indication breadth

	Tofacitinib	Baricitinib	Upadacitinib
Rheumatoid arthritis	Yes	Yes	Yes — and showed numerically higher ACR response rates vs adalimumab in head-to-head trial (SELECT-COMPARE)
Ulcerative colitis	Yes	No	Yes
Crohn’s disease	No	No	Yes
Psoriatic arthritis	Yes	No	Yes
Ankylosing spondylitis	No	No	Yes
Atopic dermatitis	No	Yes	Yes
Alopecia areata	No	Yes	No

Upadacitinib has the broadest approved indication list of the three, which is one reason it’s often considered when a patient has overlapping conditions (e.g., RA plus inflammatory bowel disease).

Side effect nuances beyond the shared boxed warnings

Tofacitinib has been associated with dose-dependent risk — the higher 10mg twice-daily dose (used for ulcerative colitis) showed greater risk signals than the 5mg RA dose in some analyses.
Baricitinib’s JAK2 activity is linked to effects on platelet counts and cholesterol more than the JAK1-selective drugs.
Upadacitinib, being more JAK1-selective, has shown a slightly different acne and herpes zoster signal in some trials, though all three carry herpes zoster risk.

Cost and access

Tofacitinib has been on the market longest and may have more established formulary positioning in some health systems, though none of these three have generic versions widely available yet in most markets.

Bottom line

For RA specifically, all three are reasonable options and head-to-head differences are often smaller than the shared class warnings suggest — the choice frequently comes down to dosing convenience (once-daily vs twice-daily), indication overlap if you have another autoimmune condition (upadacitinib’s breadth), and your prescriber’s experience with a particular agent. The cardiovascular/clotting risk screening conversation should happen regardless of which one is being considered, since the boxed warnings apply across the class.

Your rheumatologist will weigh this against your specific risk profile, prior treatment history, and any other autoimmune conditions you’re managing.

How does testing work

What screening tests are needed before starting a JAK inhibitor like baricitinib?

Pre-treatment screening for JAK inhibitors like baricitinib is fairly standardized across the drug class, given the shared boxed warnings. Here’s what’s typically involved:

Infection screening — the most critical category

Tuberculosis (TB) screening is required before starting. This usually means a TB skin test (PPD) or interferon-gamma release assay (IGRA, such as QuantiFERON-TB), often combined with a chest X-ray to check for signs of prior or latent TB. If latent TB is found, treatment for it typically needs to begin before or alongside starting baricitinib.

Hepatitis B and C screening is done via blood tests — hepatitis B surface antigen, core antibody, and surface antibody, plus hepatitis C antibody. JAK inhibitors can reactivate dormant hepatitis B, so a positive result doesn’t necessarily rule out treatment, but it changes the monitoring plan significantly and may require antiviral prophylaxis.

A general assessment for any active infection — even something that seems minor, like a urinary tract infection or skin infection — is also part of this step, since starting an immunosuppressive medication during an active infection is avoided.

Baseline blood work

Complete blood count (CBC) — checks white blood cells, lymphocytes, neutrophils, and platelets, since JAK inhibitors can lower these counts
Liver function tests (LFTs) — baseline ALT/AST, since liver enzyme elevations are monitored throughout treatment
Lipid panel — cholesterol and triglycerides, because JAK inhibitors (baricitinib in particular, given its JAK2 activity) are associated with increased cholesterol levels
Kidney function (creatinine/eGFR) — baricitinib dosing is adjusted based on kidney function, so this affects the starting dose itself

Cardiovascular and clotting risk assessment

This connects directly to the boxed warnings. Your physician will typically review:

Age (50+ being a key threshold)
Smoking history (current or past)
Blood pressure
History of heart attack, stroke, or blood clots (DVT/PE)
Diabetes
Family history of cardiovascular disease

There’s no single “test” for this — it’s a risk-factor assessment that may prompt additional baseline tests (ECG, for example) depending on what’s found.

Cancer screening considerations

Given the malignancy boxed warning, your physician may review whether you’re up to date on age-appropriate cancer screenings (such as skin checks, given increased non-melanoma skin cancer risk associated with JAK inhibitors, or other screenings relevant to your age and history).

Vaccination status review

Before starting, it’s common to review and update vaccinations — particularly the shingles (herpes zoster) vaccine, since reactivation of varicella-zoster virus is more common on JAK inhibitors. Live vaccines generally need to be completed before starting treatment, since they may not be safe to give once you’re on an immunosuppressive medication.

Pregnancy testing

For anyone of childbearing potential, a baseline pregnancy test is typically done, along with a discussion of contraception requirements during treatment.

Summary table

Category	Test/Assessment
Infection	TB test + chest X-ray, hepatitis B/C panel, active infection check
Blood work	CBC, liver function, lipid panel, kidney function
Cardiovascular	Risk factor review (age, smoking, BP, history)
Cancer	Age-appropriate screening review
Vaccines	Shingles vaccine status, live vaccine timing
Pregnancy	Baseline test if applicable

Most of these continue as ongoing monitoring after starting too — this isn’t a one-time checklist, particularly the blood counts, liver enzymes, and lipid panel, which are usually rechecked periodically throughout treatment.

This is a sensitive area where your physician’s full picture of your health history matters more than any general list — worth bringing up anything in your history that might fall into these categories, even if it seems unrelated.

Medical disclaimer: This page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Osimertinib is a prescription medication that must only be used under the supervision of a qualified oncologist. Clinical outcomes data is drawn from published Phase III trials; individual results vary. Always consult your healthcare provider and refer to the full prescribing information before making any treatment decisions. Emergency: call your local emergency services or poison control immediately if you experience serious adverse effects.